

Covalon to Showcase Centaur™ Low Particulate, Lubricious Coating at MD&M West

MISSISSAUGA, Ontario – February 5th, 2018 – /Business Wire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring its commercially available platform technologies, including the recently launched Centaur™ coating as first-time exhibitors at North America's largest annual MedTech event. MD&M West will take place at the Anaheim Convention Center, from February 6-8, 2018.

In a third party *in vitro* simulated vascular insertion study designed to measure the levels of particulate, Covalon's Centaur™ coating resulted in statistically significantly lower levels for all particulate sizes relative to the same uncoated catheter. This contrasts with other industry leading coatings that can generate nearly twice as many particles as the same uncoated catheter. Covalon's Centaur™ coating technology specifically targets and is ideally suited for a growing segment of the medical coatings market focused on improving lubricity while maintaining coating durability.

In addition to Centaur, Covalon will be featuring CovaClear™ its proprietary dual antimicrobial silicone adhesive platform, which can effectively kill 99.99% of the bacteria that it comes in contact with, reducing the risk of infection as well as diminishing the likelihood of developing a medical adhesive related skin injury or MARS, a clinically relevant and potentially avoidable event. Both platforms are available for licencing and are applicable across a variety of fields-of-use.

MD&M West connects thousands of advanced design and manufacturing professionals from the world's largest collection of medical technology suppliers with executives who are ready to forge business partnerships. To learn more about Covalon's platform technologies, visit Covalon at booth 867 during exhibit hours, or email centaur@covalon.com

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

- 30 -